China's KBP Bio is coming to America, with $76M A round and GSK vet taking the helm in Philly
Over the past 5 years KBP Biosciences has been steadily growing up its pipeline of new drugs from its base in China. But this morning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
